Literature DB >> 16759108

Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists.

Derek W Nelson1, Robert J Gregg, Michael E Kort, Arturo Perez-Medrano, Eric A Voight, Ying Wang, George Grayson, Marian T Namovic, Diana L Donnelly-Roberts, Wende Niforatos, Prisca Honore, Michael F Jarvis, Connie R Faltynek, William A Carroll.   

Abstract

1-Benzyl-5-aryltetrazoles were discovered to be novel antagonists for the P2X(7) receptor. Structure-activity relationship (SAR) studies were conducted around both the benzyl and phenyl moieties. In addition, the importance of the regiochemical substitution on the tetrazole was examined. Compounds were evaluated for activity to inhibit calcium flux in both human and rat recombinant P2X(7) cell lines using fluorometric imaging plate reader technology. Analogues were also assayed for their ability to inhibit IL-1beta release and to inhibit P2X(7)-mediated pore formation in human THP-1 cells. Compound 15d was advanced to efficacy studies in a model of neuropathic pain where significant reversal of mechanical allodynia was observed at doses that did not affect motor coordination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16759108     DOI: 10.1021/jm051202e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  71 in total

1.  P2X receptor antagonists for pain management: examination of binding and physicochemical properties.

Authors:  Rebecca J Gum; Brian Wakefield; Michael F Jarvis
Journal:  Purinergic Signal       Date:  2011-11-16       Impact factor: 3.765

2.  Development of a comprehensive set of P2 receptor pharmacological research compounds.

Authors:  R A Felix; S Martin; S Pinion; D J Crawford
Journal:  Purinergic Signal       Date:  2011-11-04       Impact factor: 3.765

Review 3.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

4.  On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079.

Authors:  Daniel Marcellino; Diana Suárez-Boomgaard; María Dolores Sánchez-Reina; José A Aguirre; Takashi Yoshitake; Shimako Yoshitake; Beth Hagman; Jan Kehr; Luigi F Agnati; Kjell Fuxe; Alicia Rivera
Journal:  J Neural Transm (Vienna)       Date:  2010-04-13       Impact factor: 3.575

5.  C-terminal calmodulin-binding motif differentially controls human and rat P2X7 receptor current facilitation.

Authors:  Sébastien Roger; Ludovic Gillet; Alberto Baroja-Mazo; Annmarie Surprenant; Pablo Pelegrin
Journal:  J Biol Chem       Date:  2010-04-08       Impact factor: 5.157

6.  Physiological and pathological functions of P2X7 receptor in the spinal cord.

Authors:  Maria Luisa Cotrina; Maiken Nedergaard
Journal:  Purinergic Signal       Date:  2009-02-11       Impact factor: 3.765

7.  Pharmacological characterization of the P2 receptors profile in the podocytes of the freshly isolated rat glomeruli.

Authors:  Daria V Ilatovskaya; Oleg Palygin; Vladislav Levchenko; Alexander Staruschenko
Journal:  Am J Physiol Cell Physiol       Date:  2013-09-18       Impact factor: 4.249

8.  Novel P2X7 receptor antagonists ease the pain.

Authors:  B F King
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

Review 9.  Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states.

Authors:  D L Donnelly-Roberts; M F Jarvis
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

Review 10.  Calcium influx pathways in breast cancer: opportunities for pharmacological intervention.

Authors:  I Azimi; S J Roberts-Thomson; G R Monteith
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.